The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/167238

Please be advised that this information was generated on 2019-02-18 and may be subject to change.
ABSTRACT

Objective: To identify information priorities for consumers and clinicians making depression treatment decisions and assess shared decision-making (SDM) in routine depression care.

Design: 20 questions related to common features of depression treatments were provided. Participants were initially asked to select which features were important, and in a second stage they were asked to rank their top 5 ‘important features’ in order of importance. Clinicians were asked to provide rankings according to both consumer and clinician perspectives. Consumers completed CollaboRATE, a measure of SDM. Multiple logistic regression analysis identified consumer characteristics associated with CollaboRATE scores.

Setting: Online cross-sectional surveys fielded in September to December 2014.

Participants: We administered surveys to convenience samples of US adults with depression and clinicians who treat depression. Consumer sampling was targeted to reflect age, gender and educational attainment of adults with depression in the USA.

Primary outcome measures: Information priority rankings; CollaboRATE, a 3-item consumer-reported measure of SDM.

Results: 972 consumers and 244 clinicians completed the surveys. The highest ranked question for both consumers and clinicians was ‘Will the treatment work?’ Clinicians were aware of consumers’ priorities, yet did not always prioritise that information themselves, particularly insurance coverage and cost of treatment. Only 18% of consumers reported high levels of SDM. Working with a psychiatrist (OR 1.87; 95% CI 1.07 to 3.26) and female gender (OR 2.04; 95% CI 1.25 to 3.34) were associated with top CollaboRATE scores.

Conclusions: While clinicians know what information is important to consumers making depression treatment decisions, they do not always address these concerns. This mismatch, coupled with low SDM, adversely affects the quality of depression care. Development of a decision support intervention based on our findings can improve levels of SDM and provide clinicians and consumers with a tool to address the existing misalignment in information priorities.

INTRODUCTION

Treatments for individuals with depression are numerous, with multiple generations of antidepressant medications and psychosocial interventions such as cognitive-behavioral and problem-solving therapies now delivered both in person and online.¹⁻⁻⁵ These treatment options do not differ substantially in effectiveness,⁶⁻⁻⁷ yet significant side effects are more commonly reported with the use of antidepressant medications.⁷⁻⁻⁸ While consumers tend to prefer psychosocial therapies,⁹ 75% of consumers use antidepressant medication and only 43% use psychosocial interventions.¹⁰ In addition, individuals with depression often do not adhere to treatment,¹¹⁻⁻¹⁴ especially with antidepressants.¹²⁻⁻¹⁴ While lack of access is an issue for some treatment options, misalignment between a consumer’s preferred treatment and prescribed treatment can contribute to low adherence and is detrimental to the
therapeutic alliance between consumer and clinician.\textsuperscript{15} Likewise, aligning treatment decisions with consumer preferences results in lower rates of treatment attrition, fewer missed appointments, higher consumer satisfaction and better clinical outcomes.\textsuperscript{16–18}

Shared decision-making (SDM) aims to generate greater alignment between patient preferences and chosen treatments with a view to improving subsequent treatment outcomes.\textsuperscript{19} When individuals with depression are involved in SDM, treatment selection, adherence, satisfaction and outcomes are improved.\textsuperscript{18, 20–21} Yet many individuals with depression experience inadequate SDM. Solberg et al.\textsuperscript{22} surveyed 1168 adults with depression in Minnesota and found moderate levels of SDM. Consumers who were older, who were in poverty, who were of poorer general health or who had been treated for longer than 6 weeks reported lower levels of SDM, although the generalisability of these results is limited given that all participants were from a primary care sample. Additionally, independent raters found very low levels of SDM across 287 audio-recorded encounters of standardised patients presenting to primary care practices with symptoms of depression.\textsuperscript{23}

These low levels of SDM are not surprising: individuals with depression often are not given time to ask questions about treatments and are dissatisfied with the amount of information they receive.\textsuperscript{24} Decision support intervention tools (DESI) have been suggested as a solution.\textsuperscript{25} DESIs increase patient knowledge about treatment options and have the potential to enhance consumer–clinician communication.\textsuperscript{26} DESI use has been shown to help patients develop more informed, preference-led treatment choices.\textsuperscript{26} Issue cards, decision boxes and option grids are examples of brief tools for use during clinic visits that are shown to increase SDM.\textsuperscript{27} However, few DESIs have been designed and tested for English-speaking patients with depression,\textsuperscript{28} and those that focus exclusively on comparing medication options and do not include evidence about other equally effective psychosocial treatments.\textsuperscript{29} To date, only one DESI, developed and tested in German, includes information on medication and psychotherapy.\textsuperscript{30} Early studies of the existing DESIs are promising, indicating increases in consumer engagement, satisfaction, knowledge, reductions in decisional conflict and no difference in consultation time.\textsuperscript{29, 30}

DESI development requires an understanding of the information considered important by both healthcare consumers and healthcare professionals. A search for previous work addressing this issue did not identify any relevant studies.

We aimed to address this gap by identifying the information most important to consumers and clinicians when making depression treatment decisions and assess the extent of SDM in routine depression care as reported by consumers.

\textbf{METHODS}

\textbf{Participants}

We administered parallel cross-sectional national surveys between September 2014 and January 2015 to convenience samples of: (1) individuals who were currently being treated, were awaiting treatment or had previously been treated for depression; and (2) clinicians who had recently treated individuals with depression. Dartmouth College’s Committee for the Protection of Human Subjects (CPHS) considered this project exempt from Institutional Review Board (IRB) review. All surveys were completed online and hosted by Qualtrics (Qualtrics LLC, Provo, Utah, USA).

\textbf{Consumers}

Consumers were eligible for inclusion if they had ever been diagnosed with, counselled about or treated for depression; were aged 18 years or older; resided in the USA; and were comfortable reading and writing in English.

\textbf{Clinicians}

Clinicians were eligible for inclusion if they counselled, diagnosed or treated a person with depression in the prior 12 months; practised in the USA; and were comfortable reading and writing in English. We define clinician to include primary care physicians (including internal and family medicine), psychiatrists, psychologists, psychiatric/mental health nurses, social workers and licensed professional counsellors.

\textbf{Recruitment}

Participants were recruited from convenience samples. Approximately 15 US-based healthcare organisations and consumer advocacy groups shared a hyperlink to the survey via email, listserv, social media (Facebook and Twitter) or personal communication (see online supplementary appendix 1 for details).

To ensure the sample of consumer respondents matched population distributions, we adopted recruitment quotas based on epidemiological data.\textsuperscript{31} These quotas helped to approximate the lifetime prevalence of depression among US adults with regard to age, gender and educational attainment. Similar data were not available for the clinician sample.

We used paid advertising via Facebook to target male consumers due to low survey uptake. We supplemented clinician recruitment with respondents from Qualtrics Panels (Qualtrics LLC, Provo, Utah, USA).

\textbf{Measures}

We developed a 53-item patient survey and a 63-item clinician survey (see online supplementary appendices 2 and 3). The surveys used a combination of validated, adapted and newly developed questions (more detail is provided below). The surveys were informally piloted with local clinicians, research staff and consumer
representatives to assess survey duration, flow and ease of interpretation. Our approach modelled that of a recent survey investigating what matters most to individuals facing contraception decisions.\textsuperscript{32}

**Patient survey**

The patient survey consisted of five sections: sociodemographics, health status, treatment experience, information priorities and SDM. The information priorities section consisted of 20 frequently asked questions (FAQs) deemed pertinent to depression treatment decision-making based on a literature review of peer-reviewed journal articles, guidelines, existing decision support tools for depression and stakeholder input. Respondents were also given an opportunity to list additional information priorities within the survey. Sociodemographic questions were based on US Census items;\textsuperscript{33–36} questions on health status (comorbidities, current depression status) and treatment experience (treatment history, treating clinician) were developed for this study.

To assess information priorities, consumers were asked to rate 20 FAQs on a five-point Likert-type importance scale in response to the question, ‘How important is each of these questions to you when choosing a treatment for depression?’ Responses ranged from ‘extremely unimportant’ to ‘extremely important’ with an additional ‘don’t know what this means’ response option. FAQs were divided into five blocks covering four content areas: the process of receiving treatment, lifestyle impact, side effects and financial considerations. The presentation of item blocks and items within blocks was randomised to avoid order effects. FAQs marked either important or very important were then included together on a subsequent webpage and ranked by respondents to ascertain the top five information priorities. The same process was followed for side effects: where ‘side effects’ were marked important or extremely important, respondents were asked to rank the top 5 from a list of 12 commonly reported side effects.

Consumers were also asked to complete CollaboRATE, a three-item validated measure of SDM, based on the most recent clinical encounter where depression was discussed.\textsuperscript{37,38} The items are: (1) How much effort was made to help you understand your health issues? (2) How much effort was made to listen to the things that matter most to you about your health issues? (3) How much effort was made to include what matters most to you in choosing what to do next? Each of the three items was rated on a scale of 0 (no effort was made) to 9 (every effort was made).

**Clinician survey**

The clinician survey consisted of five sections: sociodemographics, practice setting, depression treatment experience, information priorities and SDM. To assess information priorities, clinicians followed the same process as consumers. Clinicians were asked to answer the questions from two perspectives: (1) their own perspective as clinicians (‘In order to treat your patients’ depression, how important do you think it is to discuss the following questions?’); and (2) the consumer perspective (‘In your experience, how important do patients believe the following questions are when choosing a treatment for depression?’).

**Analysis**

We used weighted scores to assess the five most important FAQs from each of three perspectives: (1) the consumer’s perspective; (2) the clinician’s personal perspective; and (3) the clinician’s view of the consumer perspective.

FAQs within a respondent’s top five were assigned weights based on their ranked order. The most important FAQ received five points, the second most important FAQ received four points, and so on, with the fifth most important FAQ receiving one point. FAQs outside the top five did not receive any points as respondents were asked to rank only their top five. Overall points per FAQ were summed and FAQs were rank-ordered; the FAQ with the most points was considered the most important. The same weighting procedure was used to rank side effects. Subgroup analyses of rankings were conducted by consumer age, gender and educational attainment, and by clinician practice specialty.

To assess the impact of consumers’ sociodemographic characteristics and treatment experience on their experiences of SDM, we conducted multiple logistic regression analysis with CollaboRATE top score as the outcome variable.\textsuperscript{38} The highest possible CollaboRATE scores (ie, 27) were coded with a value of ‘1’; all lower scores were coded ‘0’. We calculated the average predicted probability of obtaining a CollaboRATE score adjusting for all other variables in the model. The top score is a validated method of scoring CollaboRATE and allows more meaningful interpretation of the score, namely, the proportion of consumers who perceived a highest possible quality SDM process compared with those who felt there was some room for improvement.

Individual item analysis used pairwise deletion, while the regression analysis used listwise deletion. Analyses were conducted using Stata V.13 (StataCorp LP, College Station, Texas, USA). All tests were considered statistically significant at p≤0.05.

**Sample size**

We planned to recruit a sample of 1000 consumers, which in a similarly sized probability sample would provide 95% confidence of estimating the population’s information priorities to within±3%. This also allowed for a minimum of 10 observations per parameter in the multiple logistic regression model of CollaboRATE top scores.\textsuperscript{39} We targeted a minimum of 30 responses per clinician specialty and purposefully sought more primary care physicians than psychiatrists, as approximately 30%
of all outpatient visits (initial or follow-up) for depressive disorders occur in primary care.40

RESULTS
Participants
In total, 1557 consumers began the survey, 1096 met all eligibility criteria and 972 attempted to answer survey questions. For the 972 consumers who attempted survey questions, median completion time was 12 min. Five consumers spent longer than 24 h on the survey. In total, 471 clinicians began the survey, of whom 300 met all eligibility criteria and 244 attempted to answer survey questions. Clinicians’ median completion time was 11 min, with one clinician spending longer than 24 h on the survey.

The sociodemographic profile of consumer respondents (table 1) approximated lifetime prevalence of major depressive disorder in the USA on age and gender.31 Consumer respondents were mostly female (n=664/967; 69%), Caucasian (n=716/776; 92%) and covered a diverse range of ages (mean 43.17, SD 13.41). Many had comorbid anxiety disorders (n=649/953; 67%) and a majority had at least some postsecondary education (n=615/786; 79%).

Consumer respondents were predominantly still in treatment (n=756/972; 78%) and reported their principal clinicians to be therapists (n=338/968; 35%), psychiatrists (n=327/968; 34%) or primary care physicians (n=235/968; 24%). Antidepressants were the most common treatment used (n=901/970; 93%), with talk therapy (n=703/970; 72%) and lifestyle changes (n=412/970; 42%) also commonly reported (table 2).

Clinician respondents were distributed across a variety of clinical specialties, with therapists (n=109/
Prescribers (PCPs and psychiatrists) to non-prescribers (therapists), prescribers say they most often request antidepressants alone (55%) followed by combination therapy (33%) and talk therapy (3%), while non-prescribers instead favour talk therapy (59%) and combination therapy (34%) over solely medication (1%).

What matters most in treatment decision-making

Consumer perspective

The 742 consumers who answered ranking questions felt the most important information when making a treatment decision was ‘Will the treatment work?’, followed by ‘What are the side effects of this treatment?’, ‘Is the treatment covered by insurance?’, ‘How long before I feel better?’ and ‘How much does this treatment cost?’ (table 4). Consumers’ most concerning potential side effect was increased risk of suicide, followed by sleep issues, weight change, heart problems and increased stress (see online supplementary appendix 4).

Importance rankings did not show evidence of variation by consumer age, gender or educational attainment (analysis available on request).

Clinician perspective: What consumers need to know

Two hundred and two clinicians completed rankings of what they perceived to be most important in depression treatment decisions. When considering the information priorities from their professional perspectives, clinicians

**Table 2** Demographic profile of clinician respondents

| Characteristic                | Number of clinicians (%) |
|------------------------------|--------------------------|
| Specialty                    | n=244                    |
| Therapist*                   | 109 (45)                 |
| Primary care/internal medicine physician | 81 (33)                  |
| Psychiatrist                  | 25 (10)                  |
| Psychiatric/mental health nurse | 6 (3)                    |
| Other                         | 23 (9)                   |
| Proportion of past year’s clients with depression | n=243 |
| A majority                    | 67 (28)                  |
| A substantial portion         | 151 (62)                 |
| Few                           | 25 (10)                  |
| Preferred treatment           | n=241                    |
| Combination talk therapy and medication | 75 (31)                  |
| Talk therapy                  | 75 (31)                  |
| Antidepressant medication     | 65 (27)                  |
| Lifestyle changes             | 18 (7)                   |
| Alternative therapy           | 6 (2)                    |
| Electroconvulsive therapy     | 2 (1)                    |
| Community environment (workplace) | n=205                  |
| Urban/metropolitan (50 000+)   | 84 (41)                  |
| Large rural city/ micropolitan | 53 (26)                  |
| (10 000–49 999)               |                          |
| Small rural city/ town (2500–9999) | 61 (30)                  |
| Isolated rural town (under 2500, 60+min to urban area) | 7 (3)            |
| Race†                         | n=204                    |
| White                        | 179 (88)                 |
| Asian                        | 18 (9)                   |
| African-American             | 6 (3)                    |
| American Indian or Alaska Native | 4 (2)                    |
| Native Hawaiian or Pacific Islander | 0 (0)                  |
| Other                        | 1 (0)                    |
| Ethnicity                    | n=203                    |
| Not Hispanic/Latino          | 194 (96)                 |
| Hispanic/Latino              | 9 (4)                    |
| Language spoken at home      | n=243                    |
| English                      | 212 (87)                 |
| Other                        | 31 (13)                  |

*Therapist* describes non-prescribing clinicians including psychologist, social worker and licensed professional counsellor.
†Multiple selections allowed.

**Table 3** Consumer treatment experience

| Characteristic                     | Number of consumers (%) |
|-----------------------------------|-------------------------|
| Treatment status                  | n=972                   |
| Currently in treatment            | 756 (78)                |
| Treated in the past               | 169 (17)                |
| Awaiting treatment                | 47 (5)                  |
| Primary treating clinician        | n=968                   |
| Therapist or psychologist         | 338 (35)                |
| Psychiatrist                      | 327 (34)                |
| Primary care doctor               | 235 (24)                |
| Other                             | 47 (5)                  |
| Not sure                          | 21 (2)                  |
| Most recent consultation about depression | n=789                   |
| Less than a week ago              | 183 (23)                |
| 1 week to 1 month ago             | 222 (28)                |
| 1–6 months ago                    | 214 (27)                |
| 6–12 months ago                   | 60 (8)                  |
| 12 or more months ago             | 110 (14)                |
| Treatments used (lifetime)*       | n=970                   |
| Antidepressant medication         | 901 (93)                |
| Talk therapy                      | 703 (72)                |
| Lifestyle changes                 | 412 (42)                |
| Alternative therapy               | 141 (15)                |
| Electroconvulsive therapy         | 46 (5)                  |
| Deep brain stimulation            | 9 (1)                   |

*Multiple selections allowed.
Clinician perspective: What consumers want to know

One hundred and seventy-two clinicians completed rankings of what they believe their clients find most important when making a treatment decision. When considering the importance of the information priorities from a consumer’s perspective, clinicians included the same priorities as consumers but in a different order (table 4). ‘Will the treatment work?’ again ranked number 1, followed by ‘How long before the patient feels better?’, ‘How much does the treatment cost?’ and ‘Is the treatment covered by insurance?’ and ‘What are the side effects of this treatment?’.

Engagement in care

Only 18% (n=144/781) of consumers reported a CollaboRATE top score, indicating that a majority of consumer respondents perceived low levels of SDM in their most recent clinical encounters. Many consumers (n=405/789; 51%) had their most recent visits within the previous month (table 2).

CollaboRATE top scores were more likely where the respondents were female (OR 2.14, p=0.003) or where they worked with a psychiatrist (OR 1.91, p=0.025; table 5). Respondents in older age groups appeared more likely to report a CollaboRATE top score compared with those under 30 years old, with statistically significant associations found in the 40–49 years old and over 60 years old groups (table 5). Yet when age was analysed as a continuous variable, no association between age and CollaboRATE top score was found (analysis available on request). The probability of a CollaboRATE top score where a consumer worked with a psychiatrist was 24.5% (95% CI 18.7% to 30.3%), 18.5% when working with a therapist (95% CI 13.4% to 23.6%) and 14.8% when working with a primary care physician (95% CI 8.9% to 20.7%). The predicted probability of females reporting a CollaboRATE top score was 22.0% (95% CI 18.2% to 25.9%) compared with males, 12.2% (95% CI 7.4% to 16.9%).

DISCUSSION

The information priorities of individuals with depression in the USA are not always aligned with those of clinicians. Consumers and clinicians agree that effectiveness of treatment, side effects and speed of recovery are important. While treatment costs and insurance coverage are a higher priority for consumers, explanations of how a treatment should be used and how it works were more important for clinicians. However, when clinicians were asked to adopt a consumer perspective, they were able to reliably report what consumers view to be most important. For side effect rankings, there was close alignment between consumers and clinicians; however, unlike clinicians, consumers included sleep issues and increased stress related to treatment among the most

---

**Table 4** Top five information priorities

| Information priority                                      | Weighted score | N    |
|----------------------------------------------------------|----------------|------|
| Clinicians, from clinician perspective                    |                |      |
| #1 Will the treatment work?                              | 566            | 202  |
| #2 How long before the patient feels better?             | 348            |      |
| #3 What are the side effects of this treatment?          | 318            |      |
| #4 How does the treatment work?                          | 242            |      |
| #5 What is involved in using the treatment?              | 224            |      |
| Total                                                    |                | 202  |
| Clinicians, from patient perspective                     |                |      |
| #1 Will the treatment work?                              | 469            | 172  |
| #2 How long before the patient feels better?             | 380            |      |
| #3 How much does the treatment cost?                     | 266            |      |
| #4(tie) Is the treatment covered by insurance?           | 232            |      |
| #4(tie) What are the side effects of this treatment?     | 232            |      |
| Total                                                    |                | 172  |
| Patients                                                 |                | 782  |
| #1 Will the treatment work?                              | 1524           |      |
| #2 What are the side effects of this treatment?          | 1407           |      |
| #3 Is the treatment covered by insurance?                | 1224           |      |
| #4 How long before I feel better?                        | 1147           |      |
| #5 How much does this treatment cost?                    | 984            |      |
| Total                                                    |                | 782  |

ranked ‘Will the treatment work?’ first, followed by ‘How long before the patient feels better?’, ‘What are the side effects of this treatment?’, ‘How does the treatment work?’ and ‘What is involved in using the treatment?’ (table 4). These information priorities diverged from those of consumers in the area of cost and insurance coverage.

Slight differences in information priority rankings by clinician type are outlined in online supplementary appendix 5. PCPs and psychiatrists ranked ‘Will this treatment affect other existing health conditions?’ much higher than therapists. Psychiatrists and therapists ranked ‘What is involved in using this treatment?’ higher than PCPs, while ‘How much does the treatment cost?’ was ranked higher by PCPs than by psychiatrists or therapists. The most concerning potential side effect for clinicians was increased risk of suicide, followed by drug–drug interactions, heart problems, weight change and sexual issues (see online supplementary appendix 2).
concerning side effects. A lack of SDM observed in the context of depression treatment decisions may explain this misalignment in information priorities.

**Interpretation of findings**

This is the first study to identify and compare consumers’ and clinicians’ information priorities when considering depression treatment decisions. It is reassuring to find alignment in several areas and promising to observe that clinicians are aware of consumer information priorities. However, clinicians do not prioritise insurance and cost information, despite realising its importance to consumers. The importance of cost and insurance information to consumers is consistent with previous literature.41 42 The low priority we found clinicians give to cost and insurance coverage information supports previous research on frequency of clinician–consumer communication about out-of-pocket costs.43 This lack of communication has been attributed to time limitations within clinical encounters, the challenge of identifying consumer-specific costs, and a belief that medical decisions should be based exclusively on needs, not costs.44 45 Yet the cost of treatment has a significant impact on consumer well-being, financial stability, adherence and eventual health status.46

In contrast to other studies across many conditions47 48 where CollaboRATE scores average around 70%, only 18% of individuals with depression reported a top score on CollaboRATE. Our findings support previous studies where consumers with depression report low SDM in primary care and extend this result to other clinical specialties.22 23 Female consumers were more likely to report higher CollaboRATE scores. This may be explained by previous research indicating females’ preference for more active roles in decision-making.49 While SDM was low across all clinician types, primary care physicians scored significantly lower than psychiatrists. These low scores may result from additional time pressures, as Tai-Seale et al.50 reported that a sample of primary care clinicians treating patients with mental health needs spent on average only 2 min per visit on mental health issues. Despite these differences in CollaboRATE scores by clinician type, we can conclude that consumers generally perceived low levels of SDM.

**Table 5 Analysis of CollaboRATE top scores**

| Clinician most frequently seen                  | OR (95% CI) | OR (95% CI) | Unadjusted proportion (n) | Adjusted predicted proportion (95% CI) |
|------------------------------------------------|-------------|-------------|---------------------------|---------------------------------------|
| Primary care physician                         | 1.00 (reference) | 1.00 (reference) | 14% (25) | 15 (9 to 21) |
| Psychiatrist                                   | 1.80 (1.08 to 3.00) | 1.87 (1.07 to 3.26) | 23% (62) | 24 (19 to 30) |
| Therapist                                      | 1.39 (0.82 to 2.34) | 1.31 (0.73 to 2.34) | 19% (51) | 19 (13 to 24) |
| Other/not sure                                 | 0.72 (0.28 to 1.87) | 0.80 (0.30 to 2.13) | 11% (6) | 12 (3 to 21) |
| Age 18–29                                      | 1.00 (reference) | 1.00 (reference) | 13% (19) | 13 (7 to 19) |
| 30–39                                          | 1.82 (0.99 to 3.35) | 1.85 (0.96 to 3.54) | 21% (34) | 21 (14 to 28) |
| 40–49                                          | 2.26 (1.26 to 4.03) | 2.10 (1.11 to 3.97) | 24% (48) | 23 (17 to 30) |
| 50–59                                          | 1.09 (0.58 to 2.09) | 1.24 (0.62 to 2.48) | 14% (24) | 15 (9 to 21) |
| 60+                                            | 2.05 (1.01 to 4.13) | 2.49 (1.14 to 5.43) | 23% (19) | 27 (16 to 37) |
| Treatments used                                |             |             |             |                                       |
| Antidepressant medication only                 | 1.00 (reference) | 1.00 (reference) | 12% (14) | 14 (7 to 22) |
| Medication and other treatment                 | 1.92 (1.06 to 3.46) | 1.52 (0.80 to 2.91) | 20% (124) | 20 (17 to 24) |
| Non-medication treatment                       | 0.99 (0.36 to 2.74) | 0.93 (0.29 to 3.00) | 12% (6) | 13 (2 to 25) |
| Gender                                         |             |             |             |                                       |
| Male                                           | 1.00 (reference) | 1.00 (reference) | 12% (25) | 12 (7 to 17) |
| Female                                         | 2.00 (1.26 to 3.18) | 2.04 (1.24 to 3.34) | 21% (119) | 22 (18 to 26) |
| Treatment status                               |             |             |             |                                       |
| Currently being treated                        | 1.00 (reference) | 1.00 (reference) | 19% (118) | 19 (15 to 22) |
| Awaiting treatment                             | 0.87 (0.35 to 2.14) | 0.93 (0.33 to 2.62) | 17% (6) | 18 (3 to 33) |
| Treated in the past                            | 0.78 (0.47 to 1.32) | 0.98 (0.56 to 1.71) | 16% (20) | 19 (11 to 26) |
| Education level                                |             |             |             |                                       |
| High school or less                            | 1.00 (reference) | 1.00 (reference) | 20% (31) | 22 (15 to 29) |
| Some college to Bachelor’s degree              | 0.93 (0.59 to 1.47) | 0.77 (0.47 to 1.27) | 19% (85) | 18 (14 to 22) |
| Graduate/professional degree                   | 0.96 (0.54 to 1.69) | 0.77 (0.42 to 1.44) | 19% (28) | 18 (11 to 25) |
| Health insurance status                        |             |             |             |                                       |
| Private health insurance                       | 1.00 (reference) | 1.00 (reference) | 19% (86) | 19 (15 to 23) |
| Public health insurance                        | 1.22 (0.78 to 1.90) | 1.06 (0.66 to 1.71) | 23% (35) | 20 (13 to 26) |
| No insurance                                   | 0.88 (0.48 to 1.61) | 0.89 (0.47 to 1.69) | 17% (15) | 17 (9 to 25) |

Bold typeface indicates significance level of p<0.05.
Strengths and limitations

Though our convenience sampling approach eliminates confidentiality concerns associated with preidentifying individuals with depression across the USA, we are as a result unable to determine response rates and lack true representativeness; a probability sample would address this concern. However, by ensuring that the respondent sample approximated epidemiological data on lifetime depression prevalence with regard to age and gender, we reduced the potential impact of selection bias. In addition, clinicians in our survey are likely to treat a broad spectrum of individuals with depression; therefore, a wide range of consumers inform their views of what is most important to consumers. That these views match the views prioritised by the consumer sample is reassuring. As we were unable to target clinician sampling due to a lack of relevant data, the potential for selection bias remains a concern.

Additionally, independent clinician and consumer samples preclude direct comparisons between the groups. Further research is needed to address convergence or divergence of information priorities within clinician–consumer dyads. However, broad inclusion criteria for consumers and clinicians enabled thorough representation of depression care in the USA, evident by consumer responses from 49 of 50 US states and the District of Columbia.

Implications

While clinicians are aware of what matters most to consumers with depression, they do not always prioritise this information. Low SDM combined with a misalignment in information priorities between consumers and clinicians may explain why consumers often do not receive their preferred treatments.51

Better equipping clinicians to talk to consumers about information central to consumer decision-making, such as the cost and insurance coverage associated with different treatment options, can lead to more engaged and empowered consumers. This is of particular interest given the expansion of mental health coverage and depression screening resulting from the Patient Protection and Affordable Care Act. Despite previous research finding an association between SDM and higher consumer satisfaction in depression care,21 routine clinician training in SDM is still lacking. The current work can help inform development of a DESI for depression that consists of key information priorities identified by consumers and clinicians. These tools have demonstrated promise in treating other conditions and may help facilitate clinician–consumer conversations in depression care, leading to better informed consumers choosing treatments that are right for them. We are currently in the process of developing a DESI based on our findings and testing understanding, comprehensiveness and acceptability with key stakeholders (consumers, general public and clinicians) through cognitive interviews.

CONCLUSION

While consumers and clinicians agreed on some information priorities for depression treatment decision-making, there was misalignment in the area of treatment cost and insurance coverage despite clinician awareness of the importance of these issues to consumers. The low levels of SDM reported by consumers with depression emphasise the impact of this priority mismatch. Future work on interventions to improve depression treatment decision-making may help narrow the existing gap between consumers’ and clinicians’ information priorities and increase SDM, leading to treatments aligned with consumer preferences.

Twitter Follow Paul Barr at @BarrPaulJ

Acknowledgements The authors thank the following individuals and groups for their contributions to our study: Jim Matthews for comments on the manuscript; Bob Drake and Mark Hegel of Dartmouth College for feedback and advice on initial drafts of the surveys; Greg McHugo of Dartmouth College for advice on study design; James O’Malley for advice on data analysis; and organisations listed in online supplementary appendix 1 for help with recruitment.

Contributors PJB conceived of the study and contributed to the design of the work, interpretation of data, and drafting and revision of the manuscript. RCF contributed to the design of the work, data analysis, interpretation of data and drafting and revision of the manuscript. MM contributed to the design of the work, interpretation of data and revision of the manuscript. GB contributed to the design of the work and drafting of the manuscript. GE contributed to the design of the work and drafting and revision of the manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests GE reports grants and personal fees from the Informed Medical Decision Making Foundation, personal fees from Emmi Solutions LLC, outside the submitted work. As two of the copyright holders of CollaboRATE, GE and PJB wish to declare this intellectual conflict of interest. CollaboRATE is freely available under a Creative Commons License for non-commercial use: CC BY-NC-ND 3.0 Unported. GE also wishes to declare an intellectual competing interests as the founder of the Option Grid Collaborative. Option Grids are freely available under a Creative Commons License for non-commercial use: CC BY-NC-ND 4.0.

Ethics approval Dartmouth College Committee for the Protection of Human Subjects.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161–78.
2. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26:17–31.
3. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013;10:e1001454.
4. Cuijpers P, Berking M, Anderson G, et al. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in
comparison with other treatments. Can J Psychiatry 2013;58:376–85.
5. Richards D, Richardson T. Computer-based psychological treatments for depression: a systematic review and meta-analysis. Clin Psychol Rev 2012;32:329–42.
6. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252–60.
7. Bet PM, Hugtenburg JG, Penninx BWJH, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol 2013;23:1443–51.
8. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959–65.
9. Van Schaik DJF, Klijn AFJ, van Hout HJP, et al. Patients’ preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2004;26:184–9.
10. Marcus SC, Oldep M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010;67:1265–73.
11. Swift JK, Greenberg RP. Premature discontinuation in adult psychotherapy: a meta-analysis. J Consult Clin Psychol 2012;80:547–59.
12. Peveler R, George C, Kinmonth A-L, et al. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 1999;319:612–15.
13. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006;44:300–3.
14. Pampallona S, Bollini P, Tibaldi G, et al. Patient adherence in the treatment of depression. Br J Psychiatry 2002;180:104–9.
15. Kwan BM, Dimidjian S, Rizvi SL. Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behav Res Ther 2010;48:799–804.
16. Rokke PD, Tomhave JA, Jocic Z. The role of client choice and target selection in self-management therapy for depression in older adults. Psychol Aging 1999;14:155–69.
17. Lin P, Campbell DG, Chaney EF, et al. The influence of patient preference on depression treatment in primary care. Ann Behav Med 2005;30:164–73.
18. Lindhjem O, Bennett CB, Trentacosta CJ, et al. Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. J Consult Clin Psychol 2014;82:506–17.
19. Raue PJ, Schulberg HC, Lewis-Fernandez R, et al. Shared decision-making in the primary care treatment of late-life major depression: a needed new intervention? Int J Geriatr Psychiatry 2010;25:1101–11.
20. Christensen H, Griffiths KM, Gulliver A, et al. Models in the delivery of depression care: a systematic review of randomised and controlled intervention trials. BMC Fam Pract 2008;9:25.
21. Swanson KA, Bastani R, Rubenstein LV, et al. Effect of mental health care and shared decision making on patient satisfaction in a community sample of patients with depression. Med Care Res Rev 2007;64:416–30.
22. Solberg LI, Crain AL, Rubenstein L, et al. How much shared decision making occurs in usual primary care of depression? J Am Board Fam Med 2014;27:199–208.
23. Young HN, Bell RA, Epstein RM, et al. Physicians’ shared decision-making behaviors in depression care. Arch Intern Med 2008;168:1404–8.
24. Simmons MB, Hetrick SE, Jorm AF. Experiences of treatment decision making for young people diagnosed with depressive disorders: a qualitative study in primary care and specialist mental health settings. BMC Psychiatry 2011;11:194.
25. Clever SL, Ford DE, Rubenstein LV, et al. Primary care patients’ involvement in decision-making is associated with improvement in depression. Med Care 2006;44:398–405.
26. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;1:CD001431.
27. Wyatt KD, Brandia ME, Inselsman JW, et al. Genders of patients and clinicians and their effect on shared decision making: a participant-level meta-analysis. BMC Med Inform Decis Mak 2014;14:81.
28. Duncan E, Best C, Hagen S. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev 2010;(1):CD007297.
29. LeBlanc A, Herrin J, Williams MD, et al. Shared decision making for antidepressants in primary care: a cluster randomized trial. JAMA 2012;307:1761–70.
30. Loh A, Simon D, Willis CE, et al. The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Couns 2007;67:324–32.
31. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62:1097–106.
32. Donnelly KZ, Foster TC, Thompson R. What matters most? The content and concordance of patients’ and providers’ information preferences for contraceptive decision making. Contraception 2014;90:280–7.
33. Ryan C. Language use in the United States: 2011. US Census Bureau, 2013.
34. Labour Educational Attainment—US Census Bureau. https://www.census.gov/hhes/socdemo/education/about/ (accessed 30 Oct 2015).
35. Humes KR, Jones NA, Ramirez RR. Overview of race and Hispanic origin: 2010. US Census Bureau, 2011.
36. Kreider RM, Simmons T. Marital status: 2000. US Census Bureau, 2003.
37. Elwyn G, Barr PJ, Grande SW, et al. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. Patient Educ Couns 2013;93:102–7.
38. Barr PJ, Thompson R, Walsh T, et al. The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res 2014;16:e2.
39. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–8.
40. Centers for Disease Control and Prevention. Selected patient and provider characteristics for ambulatory care visits to physician offices and hospital outpatient and emergency departments: United States, 2009–2010. FastStats, 2010. http://www.cdc.gov/nchs/data/ahcd/comboed_tables/AMC_2009–2010_comb_web_table1.pdf (accessed 9 Jun 2015).
41. Dunlea R, Lenert L. Understanding patients’ preferences for referrals to specialists for an asymptomatic condition. Med Decis Making 2015;35:691–702.
42. Tseng C-W, Waltzfielder BE, Tiemy EF, et al. Patients’ willingness to discuss trade-offs to lower their out-of-pocket drug costs. Arch Intern Med 2010;170:1502–4.
43. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:953–8.
44. Alexander GC, Casalino LP, Tseng C-W, et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med 2004;19:856–60.
45. Blumenthal-Barby JS, Robinson E, Cantor SB, et al. The neglected topic: presentation of cost information in patient decision AIDS. Med Decis Making 2015;35:412–18.
46. Ubel PA, Abernethy AP, Zafar SY. Full disclosure and preferences for referrals to specialists for an asymptomatic condition. Med Decis Making 2000;20:398–405.
47. Thomson R, Nye A, Walker E, et al. From bariatric surgery to vasectomy: how much shared decision making takes place in routine health care? International Shared Decision Making Conference; 2015.
48. Thompson R, Nye A, Walker E, et al. From bariatric surgery to vasectomy: how much shared decision making takes place in routine health care? International Shared Decision Making Conference; 2015.
49. Blumenthal-Barby JS, Robinson E, Cantor SB, et al. The neglected topic: presentation of cost information in patient decision AIDS. Med Decis Making 2015;35:412–18.
50. Ubel PA, Abernethy AP, Zafar SY. Full disclosure and preferences for referrals to specialists for an asymptomatic condition. Med Decis Making 2000;20:398–405.
51. Wright-Johnson M, Unutzer J, Shebourne C, et al. Can quality improvement programs for depression in primary care address patient preferences for treatment? Med Care 2001;39:934–44.